Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shuken Boku

Showing results (1-10 of 87) with videos related to

Pageof 9
Sort By:
Psychiatry and Clinical Neurosciences|October 10, 2014
Psychopharmacology of atypical antipsychotic drugs: From the receptor binding profile to neuroprotection and neurogenesisIchiro Kusumi, Shuken Boku, Yoshito Takahashi
Vitamins and Hormones|May 18, 2010
Glucocorticoids and lithium in adult hippocampal neurogenesisShuken Boku, Shin Nakagawa, Tsukasa Koyama
PCN Reports : Psychiatry and Clinical Neurosciences|October 17, 2025
Risk of diabetes mellitus with olanzapine compared to clozapine: A systematic review and meta-analysisKeigo Onda, Rizal Ichwansyah, Shuken Boku
Psychiatry and Clinical Neurosciences|September 20, 2017
Neural basis of major depressive disorder: Beyond monoamine hypothesisShuken Boku, Shin Nakagawa, Hiroyuki Toda, et al.
BMJ Case Reports|February 2, 2024
Significant efficacy of electroconvulsive therapy on the behavioural symptoms of anti-N-methyl-d-aspartate receptor encephalitisSaehyeon Kim, Kohei Horiuchi, Takehiro Ueda, et al.
Autism-Open Access|August 5, 2014
Mouse Models of 22q11.2-Associated Autism Spectrum DisorderNoboru Hiroi, Takeshi Hiramoto, Kathryn M Harper, et al.
Seishin Shinkeigaku Zasshi = Psychiatria Et Neurologia Japonica|November 2, 2005
[Atypical antipsychotic-associated impaired glucose tolerance]Shuken Boku, Yasufumi Sugawara, Miho Nakayama, et al.
Journal of Psychiatric Research|January 12, 2024
TCF7L2: A potential key regulator of antidepressant effects on hippocampal astrocytes in depression model miceYusaku Koga, Naoto Kajitani, Kotaro Miyako, et al.
Human Psychopharmacology|June 4, 2011
Olanzapine augmentation of milnacipran for stage 2 treatment-resistant major depression: an open studyShuken Boku, Takeshi Inoue, Hiroshi Honma, et al.
European Journal of Pharmacology|April 22, 2010
Combined treatment with MAO-A inhibitor and MAO-B inhibitor increases extracellular noradrenaline levels more than MAO-A inhibitor alone through increases in beta-phenylethylamineYuji Kitaichi, Takeshi Inoue, Shin Nakagawa, et al.
Pageof 9

Showing results (1-10 of 87) with videos related to

Sort By:
Pageof 9
Psychiatry and Clinical Neurosciences|October 10, 2014
Psychopharmacology of atypical antipsychotic drugs: From the receptor binding profile to neuroprotection and neurogenesisIchiro Kusumi, Shuken Boku, Yoshito Takahashi
Vitamins and Hormones|May 18, 2010
Glucocorticoids and lithium in adult hippocampal neurogenesisShuken Boku, Shin Nakagawa, Tsukasa Koyama
PCN Reports : Psychiatry and Clinical Neurosciences|October 17, 2025
Risk of diabetes mellitus with olanzapine compared to clozapine: A systematic review and meta-analysisKeigo Onda, Rizal Ichwansyah, Shuken Boku
Psychiatry and Clinical Neurosciences|September 20, 2017
Neural basis of major depressive disorder: Beyond monoamine hypothesisShuken Boku, Shin Nakagawa, Hiroyuki Toda, et al.
BMJ Case Reports|February 2, 2024
Significant efficacy of electroconvulsive therapy on the behavioural symptoms of anti-N-methyl-d-aspartate receptor encephalitisSaehyeon Kim, Kohei Horiuchi, Takehiro Ueda, et al.
Autism-Open Access|August 5, 2014
Mouse Models of 22q11.2-Associated Autism Spectrum DisorderNoboru Hiroi, Takeshi Hiramoto, Kathryn M Harper, et al.
Seishin Shinkeigaku Zasshi = Psychiatria Et Neurologia Japonica|November 2, 2005
[Atypical antipsychotic-associated impaired glucose tolerance]Shuken Boku, Yasufumi Sugawara, Miho Nakayama, et al.
Journal of Psychiatric Research|January 12, 2024
TCF7L2: A potential key regulator of antidepressant effects on hippocampal astrocytes in depression model miceYusaku Koga, Naoto Kajitani, Kotaro Miyako, et al.
Human Psychopharmacology|June 4, 2011
Olanzapine augmentation of milnacipran for stage 2 treatment-resistant major depression: an open studyShuken Boku, Takeshi Inoue, Hiroshi Honma, et al.
European Journal of Pharmacology|April 22, 2010
Combined treatment with MAO-A inhibitor and MAO-B inhibitor increases extracellular noradrenaline levels more than MAO-A inhibitor alone through increases in beta-phenylethylamineYuji Kitaichi, Takeshi Inoue, Shin Nakagawa, et al.
Pageof 9